UNSPSC 51172465: Citric acid/simethicone/sodium bicarbonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DX900. This VA Drug Class (DX900) classifies this compound as belonging to the group DIAGNOSTICS, OTHER.

UNSPSC 51172465 Citric acid/simethicone/sodium bicarbonate is a Commodity code that encompasses pharmaceutical and over-the-counter products, though recent state and local opportunities show the code capturing a broader range of pharmaceutical procurement activity than the narrow product name suggests. The actual buying under this code spans generic multi-source pharmaceuticals and OTC products distributed through state and local health systems, pharmacy benefit programs, and criminal justice agencies. Issuing bodies include state health and human services departments, state purchasing cooperatives administering multi-state agreements, and county criminal justice departments. The Minnesota Department of Administration's Office of State Procurement administers MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), which operates as a lead procuring body for multiple states and local jurisdictions; Texas Health and Human Services Commission and Texas county departments also appear as direct buyers.

Recent activity concentrates in Texas and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026 (due March 26, 2026), establishing multiple contracts effective July 1, 2026 with a two-year term. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026; while this RFP centers on testing services rather than pharmaceuticals per se, the specimen-handling and lab-confirmation scope may involve ancillary pharmaceutical materials. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling emerging state-level interest in alternative pharmaceutical distribution models outside traditional pharmacy benefit managers and group purchasing organizations.